SCHEMBL1348233

SCHEMBL1348233

Cc1[nH]c(-c2ccc(S(=O)(=O)Nc3nccs3)cc2)nc1-c1ccccc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 3/20 0.53
KMT2A Q03164 3/20 0.53
POLB P06746 2/20 0.53
SCN9A Q15858 5/20 0.52
ALDH1A1 P00352 3/20 0.50
LMNA P02545 2/20 0.50
KDM4E B2RXH2 2/20 0.50
TDP1 Q9NUW8 2/20 0.50
CYP2C9 P11712 1/20 0.50
EDNRA P25101 1/20 0.50
SLC6A4 P31645 1/20 0.50
ADRA1A P35348 1/20 0.50
PRMT6 Q96LA8 1/20 0.50
SMN1; SMN2 Q16637 1/20 0.50
SCN1A P35498 2/20 0.49
SCN5A Q14524 2/20 0.49
SCN8A Q9UQD0 2/20 0.49
SCN1B Q07699 1/20 0.49
PKM P14618 1/20 0.48
MAPT P10636 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1349837 0.88 MEN1 (0.54) MEN1KMT2APOLBSCN9AALDH1A1
SCHEMBL1349031 0.79 ALDH1A1 (0.53) MEN1KMT2ASCN9AALDH1A1LMNA
SCHEMBL326633 0.76 ALDH1A1 (0.71) MEN1KMT2ASCN9AALDH1A1LMNA
Hydrochloric Acid SCHEMBL27575105 0.75 ALDH1A1 (0.69) MEN1KMT2ASCN9AALDH1A1LMNA
SCHEMBL1350247 0.74 SCN8A (0.53) SCN9AALDH1A1LMNAKDM4ETDP1
SCHEMBL3070565 0.74 ALDH1A1 (0.68) MEN1KMT2APOLBSCN9AALDH1A1
SCHEMBL8388562 0.73 PPIA (0.76) MEN1KMT2APOLBALDH1A1LMNA
SCHEMBL714065 0.72 MEN1 (0.64) MEN1KMT2APOLBSCN9AALDH1A1
SCHEMBL31305589 0.71 NPY5R (0.68) MEN1KMT2APOLBALDH1A1KDM4E
SCHEMBL724250 0.71 NPY5R (0.72) MEN1KMT2APOLBALDH1A1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8063080-B2 Inhibitors of ion channels ICAGEN, INC. (US) 2011-11-22 US disclosed
US-20100041707-A1 INHIBITORS OF ION CHANNELS ICAGEN, INC. (US) 2010-02-18 US disclosed
US-7615569-B2 Inhibitors of ion channels ICAGEN, INC. (US) 2009-11-10 US disclosed
EP-1922068-A2 INHIBITORS OF VOLTAGE-GATED SODIUM CHANNELS Icagen, Inc. (US) 2008-05-21 EP disclosed
US-20070078145-A1 INHIBITORS OF ION CHANNELS ICAGEN (US) 2007-04-05 US disclosed
WO-2007021941-A2 INHIBITORS OF VOLTAGE-GATED SODIUM CHANNELS ICAGEN, INC. (US) 2007-02-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100041707-A1 INHIBITORS OF ION CHANNELS TRPV1, TRPA1, CACNA1B MEN1 4662/4885KMT2A 1628/4885POLB 4434/4885
US-20070078145-A1 INHIBITORS OF ION CHANNELS TRPV1, TRPA1, CACNA1B MEN1 4662/4885KMT2A 1628/4885POLB 4434/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.